Psyence Biomedical Ltd (NASDAQ: PBM)’s stock price has increased by 2.40 compared to its previous closing price of 1.67. However, the company has seen a 4.27% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-27 that NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrants in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant. The series A common warrants and short-term series B common warrants have an exercise price of $2.00 per share and are exercisable immediately upon issuance. The series A common warrants expire five years from the date of issuance and the short-term series B common warrants expire two years from the date of issuance.
Is It Worth Investing in Psyence Biomedical Ltd (NASDAQ: PBM) Right Now?
The stock has a 36-month beta value of -0.48.
The public float for PBM is 0.55M, and at present, short sellers hold a 13.83% of that float. On January 24, 2025, the average trading volume of PBM was 2.52M shares.
PBM’s Market Performance
The stock of Psyence Biomedical Ltd (PBM) has seen a 4.27% increase in the past week, with a -30.49% drop in the past month, and a -80.28% fall in the past quarter. The volatility ratio for the week is 13.48%, and the volatility levels for the past 30 days are at 15.52% for PBM. The simple moving average for the past 20 days is -12.98% for PBM’s stock, with a -93.74% simple moving average for the past 200 days.
PBM Trading at -36.60% from the 50-Day Moving Average
After a stumble in the market that brought PBM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.71% of loss for the given period.
Volatility was left at 15.52%, however, over the last 30 days, the volatility rate increased by 13.48%, as shares sank -46.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -70.66% lower at present.
During the last 5 trading sessions, PBM rose by +4.27%, which changed the moving average for the period of 200-days by -97.69% in comparison to the 20-day moving average, which settled at $1.9650. In addition, Psyence Biomedical Ltd saw -18.96% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PBM
The total capital return value is set at 108.38.
Based on Psyence Biomedical Ltd (PBM), the company’s capital structure generated -19.88 points at debt to capital in total, while cash flow to debt ratio is standing at -24.13.
Currently, EBITDA for the company is -2.75 million with net debt to EBITDA at -0.01.
Conclusion
To sum up, Psyence Biomedical Ltd (PBM) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
